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ABSTRACT1
The costs of current genotyping methods limit their application to personalized2
therapy. The authors describe an alternative approach for the detection of3
single-point-polymorphisms (SNPs) using recombinase polymerase4
amplification (RPA) as an allele-specific technique. The use of short and5
chemically modified primers, locked nucleic acids (LNA), allowed the selective6
isothermal amplification of wild-type or mutant variants at 37 C in 40 min. An7
amplification chip containing 100 wells was manufactured with a 3D printer and8
using thermoplastic polylactic acid (PLA). The platform reduces costs, reagent9
consumption, sample volume and allows assay parallelization compared to10
other amplification formats. As proof of concept, the method was applied to the11
genotyping of four SNPs that are related to the treatment of tobacco addiction.12
The target polymorphisms were rs4680 (COMT gene), rs1799971 (OPRM113
gene), rs1800497 (ANKK1 gene), and rs16969968 (CHRNA5 gene). The14
capabilities of the method are demonstrated detecting the reaction products15
using a colorimetric technique in microarray format. The genotype populations16
can be well discriminated.17
2Keywords: pharmacogenomics; SNP genotyping; isothermal amplification;18
micro-well plate; microchip; tobacco addiction; 3D-printer; COMT gene; OPRM119
gene; ANKK1 gene; CHRNA5 gene.20
3Graphical abstract21
A method based in the allele-specific recombinase polymerase amplification22
was developed for the genotyping of polymorphisms. The isothermal23
discrimination reaction was produced in a multi-well amplification chip24





Pharmacogenomics is currently considered one of the most active areas of the30
personalized medicine paradigm. However, numerous barriers have been31
encountered to launch DNA variation analyses, such as single-nucleotide32
polymorphisms (SNPs), in health systems [1]. Among other factors, available33
platforms have a marked technological limitation. Most genomic findings have34
been obtained from high-throughput technologies, such as Illumina and35
Affimetrix platforms. However, the incorporation of these methods into primary36
care centers is limited, and cost is the main drawback [2-4]. Dramatically cutting37
the turnaround times of these platforms is an important goal for implementing38
SNP testing into clinical scenarios. Therefore, the novel generation of simple39
diagnostic tools is absolutely necessary for the real adoption of personalized40
medicine [5,6].41
A large family of high-potential methods to be developed in simple systems is42
that based on allele-specific (AS) amplification [7]. Polymerase chain reaction43
(PCR) uses primer pairs, deliberately designed at SNP sites. Primers have a44
single-base variation at the 3’ end (allele-specific primers), so extension and45
amplification reactions take place with only perfectly-matched sequences of46
target regions. This approach has been successfully used as a47
pharmacogenomic tool combined with several detection systems [8-10].48
Nevertheless, these techniques require particular thermal cycling, consequently49
there are several limitations for their future integration as point-of-care devices.50
PCR demands an accurate temperature control system to quickly heat/cool51
reaction solutions. The high temperature reached (up to 95 °C) leads to52
variations in the volume reaction due to water evaporation and gas bubble53
formation, which renders accurate process control necessary.54
Several new technologies have emerged to improve DNA-based analyses [11].55
Many efforts have been made that focus on developing low-cost systems to be56
used for point-of-care applications or in small laboratories located at the57
physician’s office or in primary health centers.58
A revolution in the development of new methods is currently being witnessed,59
and is associated with the application of isothermal solutions for microanalyses60
5[12]. These approaches are based on using proteins that separate DNA strands61
instead of thermal approaches so that target nucleic acids are synthesized at62
constant temperature. Nevertheless, the application of isothermal amplification63
for SNP genotyping is still minimum [13,14]. Among isothermal reactions,64
recombinase polymerase amplification (RPA) has many interesting properties;65
e.g., short reaction times (20-60 min), robustness and low energy requirements66
(close to room temperature) [15]. Recently, our research group has67
demonstrated that polycarbonate-based substrates can be used to support RPA68
assays in chip [16], micro-reactors [17], or dynamic formats [18]. A well array69
chip has been described to process miniaturized RPA assays, applied for70
pathogen detection in under 30 min [19]. The chip was manufactured from a71
silicon substrate by a complex fabrication technique, including photolithography72
and chemical treatment, and is only available in specialized laboratories.73
The capability of RPA technology for SNP genotyping remains an unsolved74
issue. A recent study evaluated the influence of sequence mismatches on the75
amplification specificity of closely-related pathogens [20]. A proof of concept76
assay describes the discrimination of a single-point mutation of the HRAS gene77
[21]. To this end, DNA extracted from cell lines was selectively amplified and78
genetic variants were distinguished by measuring the wavelength shift on silicon79
micro-ring resonators. However, this technology is far from being adopted80
generally in health centers.81
In the present study, the capability of allele-specific RPA (AS-RPA) is evaluated82
and a low-cost method is developed for the SNP genotyping of clinically83
relevant polymorphisms. In a first approach, amplification is performed in84
conventional polypropylene vials in a single format (detection of a single85
polymorphism). The advantages of this disposable format are its low cost and86
compatibility with a huge number of laboratory equipment. However, lab-on-a-87
chip or -total analysis systems offer important advantages for diagnostic88
devices, such as high-throughput and miniaturization, among others [22].89
There are many ways to microfabricate plastic-based materials; e.g. laminate,90
embossing or injection molding. Additive manufacturing is being examined91
given its growing interest in the microfluidics field [23]. It is capable of producing92
6customized structures that range from a few microns to several centimeters in a93
single step. The main limitations of 3D printers are related to spatial resolution,94
dimensional fidelity, surface quality, biocompatibility, optical transparency,95
among others [24]. Advantages include low infrastructure costs and easy96
manufacturing compared to photolithography or soft lithography approaches. In97
order to evaluate the potential of this technology, a well array chip for98
performing AS-RPA was designed and developed with a commercial 3D printer.99
The objective was to demonstrate RPA’s capability as a genotyping method and100
to compare its performance in an advanced platform compared to the standard101
format (vials).102
As proof of concept, the solution was applied as a pharmacogenomics tool to103
treat smoking cessation and the highly addictive properties of nicotine [25,26].104
In such diseases, the benefits of personalized medicine based on genotype105
populations has been demonstrated. However, the high cost of current106
genotyping technologies, compared to the cost of ineffective or erroneous107
treatment, compromises the application of the test. Therefore, the approach108





The target polymorphisms for the tobacco use disorder were rs4680 (COMT114
gene), rs1799971 (OPRM1 gene), rs1800497 (ANKK1 gene) and rs16969968115
(CHRNA5 gene). The wild-type variants are G, A, G, and G, and the mutant116
variants are A, G, A, and A, respectively. The pharmacogenomic information117
about these variants is included as Supplementary Material (Tables SI.1, SI.2118
and SI.3). The human beta actin (ACTB) gene was selected as an endogenous119




Patient samples and reference discrimination method124
Subjects (n=17) were recruited for the present study according to ethics and125
with informed consents. Buccal smear samples were collected using sterile126
swabs. They were submitted to digestion and purification steps with a PureLink127
Genomic DNA Mini Kit (Invitrogen, Thermo Fisher Scientific, USA,128
www.thermofisher.com). The isolated DNA extracts were eluted from the spin-129
columns of the kit with Tris-HCl buffer (10 mMTris, pH 8.6) and stored at -20 °C130
until analyzed.131
Allele-specific PCR in a single format was applied as the reference genotyping132
method. Briefly, the extracted genomic DNA (4 ng) was amplified using two133
PCR master mixes (Biotools, Spain, www.biotools.eu) and employing 300 nM of134
each variant primer pair (reverse and allele-specific forward). To confirm135
amplification, products were diluted in 0.5x SyBR Safe (Invitrogen, Thermo136
Fisher Scientific, USA) and submitted to fluorescence measurements in a plate137
reader (Victor 3TM V1420, PerkinElmer, Finland, www.perkinelmer.com).138
Genotypes were also verified by 3% agarose gel electrophoresis, followed by139
dying with an intercalating agent (Real Safe, Durviz, Spain, www.durviz.com)140
and visualization under UV light.141
142
Fabrication of structured platforms143
The 100-well array chip was modeled with the Autodesk Inventor Professional144
2015 software (Autodesk, USA, www.autodesk.com) and fabricated with a 3D145
printer (Ultimaker 2 Extended, UltimakerB.V., the Netherlands,146
www.ultimaker.com). Polylactic acid (PLA) filament (RS Pro, Spain; 2.85 mm147
diameter, www.rs-online.com) was employed as the printing material.148
Fabrication was carried out using a 0.4 mm diameter nozzle at 210 °C and a149
bed operation temperature of 60 °C. In order to evaluate the best printing150
conditions, prototypes were fabricated with different layer thicknesses (up to 0.2151
mm) and at various printing speeds (up to 300 mms-1). Subsequently, printed152
8structures were cleaned with a 30-minute ultrasonic bath and dried with153
compressed air.154
The fabrication quality of the PLA-chips was monitored by optical microscopy155
imaging. Surface pictures were captured (1.2x magnification) by an Olympus156
SZ61 stereo microscope (Olympus Co., Japan, www.olympus.com). Images157
were analyzed with the Image J software to provide an estimated roughness for158
each sample. Surface hydrophobicity was estimated from the contact angle159
data. Measures of the deionized water droplets (4 L) were taken using a Dino-160
Lite Digital Microscope (AnMo Electronics Co., Taiwan, www.dino-lite.com) at161
the 1.3 megapixel resolution.162
A mass loss study was also done to evaluate possible sample evaporation on163
the platform. The chip was loaded with 10 RPA samples (4 µL each) and placed164
in an oven at 37 °C. Mass measurements of the set were periodically taken165
during 4 h and compared with those of an unloaded reference chip.166
167
Assay protocol: amplification168
The amplification step was performed using a TwistAmp Basic RPA kit169
(TwistDx, UK, www.twistdx.co.uk). Eight allele-specific mixes (2 per SNP) were170
prepared with rehydration buffer, 14 mM of magnesium acetate, 480 nM of171
allele-specific forward primer and reverse digoxigenin-labeled primer, and the172
enzyme pellet. Mineral oil (8%) was also added to minimize sample173
evaporation. Solutions were loaded onto the 100-well array chip and the DNA174
template (2.56 ng) was added to allow the simultaneous amplification of eight175
different allelic variants for 10 patient samples and controls (human ACTB176
gene). The chip was then covered with a polyester plate sealer (Corning, USA,177
www.corning.com) and gently vortexed to mix reagents and samples.178
Amplification was carried out in a heating oven (Memmert UF30, Germany,179
www.memmert.com) at 37 °C for 40 min.180
The AS-RPA reactions were also performed in 0.2 mL-polypropylene vials181
(Labbox, Spain, www.labbox.com) and polycarbonate home-made array chips.182
These chips were fabricated using a computer numerical control drilling183
9machine (Bungard CCD, Karo 5410, Germany, www.bungard.de). The feed184
speed and rotational rate of the drill were respectively 2 000 mm·s−1 and 48 000185
rpm. The diameter of each well was 5 mm and their depth was 1.1 mm. The186
composition of the RPA mixtures was the same as that previously described,187
but volumes were 25 µL and 4 µL per reaction for vials and chips, respectively.188
The heating system used was a thermocycler (TC-4000, Techne, UK,189
www.techne.com) and an oven, respectively.190
191
Assay protocol: detection and data analysis192
The AS-RPA products were detected by a hybridization assay on polycarbonate193
chips, adapted from reference [10]. Briefly, the mixtures of the wild-type or194
mutant products for all four SNPs were prepared from the respective single195
RPA solutions. For this purpose, 2 µL of each amplification product were diluted196
in 16 µL of hybridization buffer composed of NaCl 225 mM, sodium citrate 22.5197
mM, 10% formamide and 2.5x Denhardt’s solution, pH 7. Subsequently,198
mixtures were heated at 95 °C for 10 min for denaturation and transferred to the199
chips with the immobilized probes in the microarray format. After 60 min of200
incubation at 37 °C, chips were washed with diluted hybridization buffer. The201
immunoreaction protocol with enzymatic labelling was followed to develop the202
duplex of the probe-RPA product, as described in reference [10]. The oxidized203
form of 3,3',5,5'-tetramethylbenzidine (substrate of horse-radish-peroxidase)204
produced a blue precipitate over the positive or control spots. Chips were then205




The resulting gray-scale images (Tagged Image File Format, color depth 16 bit)210
were processed by an in-house software for the microarray analysis. The optical211
intensity signals of each spot and local background were quantified by212
generating a data matrix of the signal-to-noise ratios. The genotype213
determination rule was constructed according to the replicated responses of the214
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specific probes for each polymorphism. A discrimination index was calculated215
from the signal of the wild-type (WT) and mutant (MUT) variants according to216
this equation: (WT − MUT)/(WT + MUT). The Statgraphics Centurion statistical217
package for Windows v.16 was used for the data analysis.218
219
RESULTS220
RPA capability as a genotyping tool221
The use of RPA as an allele-specific amplification technique was analyzed by222
considering the role of each element in the process. A recombinase (T4 uvsX)223
recognizes targeted DNA templates and specific primers at a high affinity and224
catalyzes subsequent homologous pairing and strand exchange [20].225
Polymerase produces the correct elongation of the perfect-annealed226
primer/template, and is the key reaction in the DNA duplication process [27].227
Furthermore, the Pol I large fragment (Bsu polymerase) lacks exonuclease228
activity (3’5’) that may modify the target nucleotide. Therefore, we expected229
the presence of mismatches on their 3'-extreme to hamper the nonspecific230
reaction due to the combined action of two enzymes, even at a low working231
temperature.232
Complementarily, oligonucleotide sets were carefully selected to satisfactorily233
amplify/detect the given template region. The in silico design restrictions were234
primer length, absence of secondary structures, and primer/template duplex235
stability. Both these last parameters were estimated from the thermodynamic236
models available for DNA duplexes [28]. Although the recommended length for237
RPA primers should be 30-35 bases long according to the manufacturer’s238
instructions, shorter primers (19–21 mer) were chosen to improve selectivity.239
The free energy (G) values for the self-annealing and hairpin structures were240
restricted to 1.0 Kcalmol-1 (the equivalent to melting temperatures < 50 C).241
The selected oligonucleotides produced primer/template duplexes with changes242
in free energy (G) of -25.6±0.2 Kcalmol-1 (the equivalent to a melting243
temperature of 75.4±0.1 C) for totally complementary primers. The duplexes244
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between the template and mismatched primers were less stable (-24.0±0.6245
Kcalmol-1, 72.7±0.6 C).246
The experiments focused on evaluating discrimination capability using the247
designed primers that differentiated at their 3’-endnucleotide. Figure 1a shows248
the kinetic curve to perform amplification in a homogeneous format (reaction249
volume of 25 L). The expected positive signals were observed after 10-20 min250
following typical logistic regression (maximum response after 60 min). Under251
the selected conditions, a different behavior was observed depending on the252
added primer. Extension by polymerase was efficient when the 3’ terminal base253
of a primer matched its target, whereas extension was inefficient or nonexistent254
when the terminal base was mismatched. These effects agree with the255
previously reported results about the reduction or inhibition of the RPA reaction256







Figure 1. (a) Amplification kinetic curves of rs1799971 (OPRM1 gene)263
depending on the RPA mixture: logistic regressions y = 30 / (1+exp(-2.28 – 0.12264
t), R= 0.977 for the wild-type and y = 20 / (1+exp(-3.64 – 0.15 t)), R= 0.977 for265
the mutant variant. (b) Response depending on the primer nature and RPA266
mixture: statistical comparison compared to the perfect-match duplex (***267
p<0.001). Mixture 1: wild-type template DNA and wild-type FP). Mixture 2: wild-268
type template DNA and mutant FP. Mixture 3: mutant template DNA and wild-269
type FP. Mixture 4: mutant template DNA and mutant FP. Four replicates270
271
Conventional and chemical-modified primers, locked nucleic acids (LNA), were272
compared for AS-RPA. Figure 1b shows that nonspecific amplification took273
place for the mismatched duplexes between the primer and templates.274
Nevertheless, the amplification yield was significantly higher for the totally275
complementary duplexes (ANOVA, p-value<0.001). With the LNA primers,276
differences were more marked, and even nonspecific amplification was similar277
to the negative controls. These experiments demonstrated that the presence of278
this nucleoside at the 3’ terminal base improved allelic discrimination.279
A multiplex reaction was studied for the simultaneous amplification of more than280
one target in a single reaction. However, reaction yields were not satisfactory281
and there were sensitivity losses. One system displayed dominating and/or282
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inhibiting activity over other primers and amplicons, and even genotyping283
capability was lost. These results agreed with conventional RPA behavior and284
can be associated with their high sensitivity to the total primer concentration285
[16].286
287
Design and fabrication of well array chip288
The amplification assays, described in the previous section, were performed in289
0.2-mL polypropylene vials. The next step was to reduce the reaction volume by290
performing the assay in a well array chip. This kind of platforms improves291
amplification capabilities, particularly high-throughput [29]. Fused filament292
fabrication was chosen as the additive manufacturing technology, with a293
biocompatible polymer, e.g., PLA, as the thermoplastic material. This technique294
was selected because it produces innovative bioanalytical platforms that can be295
customer-designed and fast prototyped by a 3D printer.296
The first experiments focused on designing an array chip with 100 wells. The297
well dimensions (2.5 mm × 2.5 mm × 4 mm) were chosen to perform RPA in a298
reduced volume (<5L). Edge-to-edge spacing (distance between wells) was 1299
cm for RPA-mixture dispensation by a multi-channel micropipette. The300
deposition of filament layers, one on top of the other, built up the bottom and the301
walls of the chip. This additive technique produced grooved structured surfaces302
on chip walls to study the effect of the 3D printing parameters on chip quality303
(Supplementary Material/Figure SI.1). By increasing printing layer separation,304
groove thickness changed from 71±2 µm (0.06 mm) to 238±5 µm (0.2 mm).305
With a 0.02-mm layer height, the surface became irregular and did not produce306
visible grooves. Surface roughness, expressed in Rq, varied from 53.8 m (0.02307
mm) to 76.6 m (0.2 mm). The effect of printing speed and working308
temperatures during the deposition process were negligible. The selected309
values were a layer height of 0.1 mm and a print speed of 50 mms-1, which310
resulted in a fabrication time of 480 minunit-1. Figures 2a and 2b show the311
optical microscope images of the PLA-chips produced under the selected312
conditions. Sealing, performed with a polyester adhesive film and by adding313
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mineral oil, was effective for the tested range (up to 37 ºC and 4 h), with null314
leaking and evaporation (p-value< 0.001).315
316
Figure 2. (a) Optical microscope image of the chip wall. (b) Optical microscope317
image of chip wells (top view). (c) Effect of printing layer height on the PLA318
contact angle319
320
The hydrophilic/hydrophobic nature of the reaction vessel can affect the easy-321
filling of wells. Hence the wettability of the raw PLA-chips was estimated and322
the contact angle of well surfaces was measured. The results were 97±4  and323
77± 2  for the wall and the bottom surface, respectively. These values indicated324
how the patterned topography modified the interfacial tension between the liquid325
and thermoplastic compared to the base material (PLA, contact angle of about326
80 °). Two chemically modified chips (UV/ozone irradiation and PEG327
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passivation) were tested. The surface topographies, estimated by microscope328
image analyses, were comparable to those from the raw chip (p-value > 0.05).329
After applying soft UV/ozone irradiation, the contact angle was 71±2 . This330
lower value indicated that some photo-oxidized polar groups on the surface331
were formed, consequently fiber adhesion increased (higher surface energy).332
Addition of PEG also produced a coating over all the active surfaces, and333
hydrophilicity increased (62±3 ). Regardless of the surface treatment, reagent334
solutions were easily loaded in wells.335
The effect of the unpolished surfaces and chemical treatment on the336
amplification yield was studied. Replicate RPA reactions were performed using337
genomic DNA for native/mutant patients (order of magnitude: 103 pg of gDNA).338
Effective amplification was achieved in all the wells of the raw and chemically339
modified PLA-chips. Nevertheless, the PEG coating was chosen because this340
treatment can help block chip surfaces, and prevent nonspecific signals and341
sample losses through protein and amplification product adsorption [30].342
343
Comparison of amplification platforms344
The RPA performances for the reactions run in the PLA-3D printed chip were345
compared with two previously reported platforms (Table 1). The first reference346
platform was polypropylene vials (0.2 mL) (individual or tube strips), which are347
widely used for DNA amplification in conventional thermal cyclers. The second348
was micro-reactors fabricated in polycarbonate (PC) substrate by drilling349
because they are a low-cost alternative for reduced volume amplifications350
performed in ovens or other cheap thermal systems [17]. The analysis of351
variance (ANOVA) indicated that the responses for three platforms were352
comparable, with p-values of 0.63 for the negative controls, 0.27 for the353
reference gene (ACTB gene) and 0.23 for the target genes. The platform cost354
for 100-plex reactions using the current 3D-printed chips was the equivalent to355
those of the polypropylene vials. Nevertheless, the main advantages of this356
approach stemmed from volume reduction and the cost of the reagent; reagent357
consumption (and the amount of DNA) decreased by about 6-fold. Other358
advantages were reduced size, which was compatible with portable heating359
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systems (i.e. miniaturized Peltier-based devices), and facilitated their adaptation360
for field or doctor office applications [11,12]. These performances confirmed361
PLA-additive manufacturing to be a strategy for the rapid versatile low-cost362
prototyping of bioanalytical devices. The assay costs of each platform were363
estimated, considering their material, equipment and processing expenses (3D364
printing or CNC milling), as well as their number of parallel assays. The365
estimated platform cost per assay for the 3D printed PLA chip was similar to366
polystyrene vials, while 4-times lower than for the polycarbonate milled chips.367
Our approach based on reaction vessels was compared with microfluidic chips368
in virtue of their high applicability as point-of-care systems [31]. The microfluidic369
platforms, generally based on poly(methyl-methacrylate) (PMMA) or similar370
polymers, allow a higher degree of assay integration and lower reaction371
volumes (nanoliter scale). In exchange, the PLA multi-well chip presents easier372
manipulation, no fluidic control equipment requirements and a simpler373
fabrication process with a 16-fold lower cost.374
This study can open up ways to test PLA-microfluidic devices, e.g., integration375
of RPA amplification and real-time detection, prior to their mass production in376













Table 1. Characteristics of the tested amplification platforms389
PLA chip PP vial PC chip
Response negative
control 3 ± 2 a.u. 4 ± 1 a.u. 4 ± 1 a.u.
Response reference
gene 37 ± 3 a.u. 41 ± 2 a.u. 39 ± 3 a.u.
Response  target
genes 34 ± 3 a.u. 37 ± 1 a.u. 35 ± 1 a.u.
Fabrication
technique 3D printing Molding Molding + Milling
Platform
dimensions
52 mm × 52 mm × 10
mm 100 × (20 mm,  7 mm)










per assay 4 L 25 L 4 L
DNA amount per
assay 2.56 ng 16 ng 2.56 ng
a.u.: arbitrary units. Data from three replicated assays390
391
Analytical performance of the genotyping assay392
Having demonstrated that AS-RPA can be used for SNP genotyping in a single393
format, the capabilities of a multiplex detection method were studied. Among394
the techniques currently available (i.e. optical, electrochemical, etc.), AS-RPA395
on PLA chips combined to a hybridization assay on PC chips was tested. This396
detection approach showed excellent performance to simultaneously identify397
several PCR products [10].398
The AS-RPA products from the target genes related to the tobacco use disorder399
were simultaneously determined. Selectivity was estimated from cross-reactivity400
experiments by hybridizing products from single amplification assays on a chip401
that contained probes for the five studied genes (four target genes and a control402
gene) (Figure 3). Positive responses were obtained only for the specific probe,403
and were negative for the remaining ones. Sensitivity was determined by404
preparing heterozygous mixtures with increasing percentages of wild-type DNA405
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compared to the mutant type (Supplementary Material). Mismatched DNA was406
detected up to 5-10 %, which indicated that the system was capable of407
discriminating both genotypes selectively. Intra-day repeatability and inter-day408
reproducibility, expressed as the relative standard deviation of spot intensities409
for the replicated assays (five replicates), were 13 % and 17 %, respectively.410
The ANOVA test showed that the end-point responses were comparable for the411
four studied genes (p-value > 0.05).412
Our detection method of AS-RPA products displayed comparable performance413
to others previously described for AS-PCR, such as capillary electrophoresis414
[8], real-time fluorescence [32], the fluorescent-based droplet technique [9] and415







Figure 3. (a) Probe layout of a microarray chip (b) Microarray images obtained420
for the amplification products: rs1799971 (left) and rs1800497 (right).(c) Assay421
response depending on the percentage of wild-type template compared to the422
total template for both RPA mixtures (wild-type FP and mutant FP). Logistic423
regressions: y = 32 / (1+exp(2.43 – 0.07 t), R= 0.982 for the wild-type and y =424
37 / (1+exp(-2.80 + 0.05 t), R= -0.935 for the mutant.425
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Analysis of patient samples426
The applicability of chip-based AS-RPA for genotyping screening in tobacco427
cessation treatment, or for drugs used in nicotine dependence, was428
investigated. As a biological sample, buccal swab extracts were selected. In a429
clinical scenario, the use of buccal swabs is noninvasive, less stressful and a430
much easier technique to collect DNA samples. Moreover, sample storage does431
not require refrigeration and DNA extraction is a much simpler process than432
blood samples. As a detection strategy, a desktop scanner was used for chip433
reading. Then the procedure was performed using low-resource laboratory434
materials and equipment (i.e. a primary health center). The analysis time was435
210 min (DNA extraction: 50 min, amplification: 60 min, hybridization-detection:436
100 min).437
The absorption measurements indicated that a sufficient amount of high quality438
amplifiable human DNA was isolated from all the tested samples. The reference439
(ACTB gene) and targeted regions were amplified and submitted to on-chip440
hybridization. Figure SI.3 illustrates some examples of the microarray images.441
Presence of mutated variants in rs4680 and rs1799971 was detected. A442
subsequent comparison of the acquired chip signals with patient stratification443
based on the reference method clearly demonstrated perfect matching. The444
clinical implications of the provided genotyping results are a review of drug445
treatment, including anti-depressives or nicotine replacement products (e.g.446
patch). Functional polymorphisms in dopamine pathways (rs4680) are447
associated with the use of bupropion to mitigate lapsing to smoking following a448
quit attempt [34]. Better prolonged abstinence rates have been reported after449
the nicotine replacement therapy tailored to each smoker, and based on either450
genotype in the opioid receptor (rs1799971) [26].451
Presence of mutant alleles was detected for 70.6 % (rs4680), 52.9 %452
(rs1799971), 41.2 % (rs1800497), and 41.2 % (rs16969968) of the smoker453
patients. A discrimination factor for genotype assignment was calculated from454
the signal-to-noise ratios recorded in the microarray images (Figure 4). Each455
call type within each target polymorphism statistically and significantly differed456
from the others (p-values <0.0001). Homozygous genotypes led to457
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discrimination factors above 0.3 and under −0.3 for the wild-type and the458
mutant, respectively. An intermediate discrimination factor (between −0.3 and459
+0.3) was calculated for each heterozygous genotype. The genotype460
assignments, listed in Supplementary Material, agreed with those obtained by461
the reference method (100 % coincidence).462
463
Figure 4. Boxplots of the discrimination factors classified according to the464




In the last few decades, patient genome information has been proposed to469
select individual clinical care, particularly drug treatment decisions. However,470
the impact of personalized medicine is low compared to the research advances471
made. The results reported herein study demonstrate how pharmacogenomics472
knowledge combined with emerging analytical methodologies can benefit473
clinical practice more broadly. Although more in-depth research must be474
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conducted, the combination of two innovative solutions was a success. Firstly,475
the advantages of the isothermal amplification reaction were incorporated to476
acquire the demanded copy number for sensitive SNP loci detection. The best477
features were their fast-response (4-fold compared to the PCR), low478
temperature (37 C) and few design restrictions. However, the reduced479
multiplexing capabilities forced single parallelized reactions. Secondly, we480
employed additive manufacturing based on using a 3D printer as the chosen481
technology to create a customer-tailored platform for high-throughput analyses.482
The 100-well PLA-chip design considerably reduced reagent consumption and483
avoided expensive manufacturing processes or complex pumping systems484
associated with some DNA detection instruments. In fact the assay can be485
performed with standard materials (i.e. pipettes, oven) found in clinical486
laboratories. The present work demonstrates that PLA is an adequate material487
for performing enzymatic reactions in a static format. The following step is to488
achieve better point-of-care performance and the next challenge is to develop489
microfluidic devices fabricated with this material that integrate all DNA assay490
steps, from extraction to detection. The advantages include the method’s491
flexibility and accessibility compared to other micro-prototyping or micro-492
fabrication techniques.493
Regarding the clinical impact, today pharmacogenomics is applied mainly to494
certain treatments in psychiatry, oncology and cardiology. One main reason is495
the cost-effectiveness of genotyping methods. In addition, only some diseases496
apply to this approach because their treatment generally involves expensive497
pharmaceutical products or drugs with highly probable adverse effects. With our498
approach, personalized therapies based on incorporating genetics into patient499
stratification can be offered, and even for relatively less-impact treatments. The500
methodology’s cost-effectiveness, flexibility and portability will support the well-501
known genetic marker for predicting drug responses. In the particular case of502
tobacco addiction, genotyping information will help predict the degree of503
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